RSHN (RushNet) EBITDA Margin %: 0.00% (As of . 20)


What is RushNet EBITDA Margin %?

RushNet RSHN -99.00% EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. RushNet's EBITDA for the three months ended in . 20 was $0.00 Mil. RushNet's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, RushNet's EBITDA margin for the quarter that ended in . 20 was 0.00%.

RushNet  (OTCPK:RSHN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

RushNet EBITDA Margin % Related Terms

RushNet EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for RushNet's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RushNet EBITDA Margin % Chart

RushNet Annual Data
Trend
EBITDA Margin %

RushNet Quarterly Data
EBITDA Margin %

RSHN vs MOJO, LBIX, KRED: EBITDA Margin % Comparison

For the Diagnostics & Research subindustry, RushNet's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RushNet EBITDA Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RushNet's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where RushNet's EBITDA Margin % falls into.


RushNet EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

RushNet's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

RushNet's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
RushNet (RSHN) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RushNet and its competitors.
Is RushNet's EBITDA Margin % too high?
RushNet's current EBITDA Margin % is 0.00%.
How does RushNet's EBITDA Margin % compare to MOJO and LBIX?
RushNet's EBITDA Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RushNet and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RushNet's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RushNet stock overvalued right now?
RushNet (RSHN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For RushNet (RSHN), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RushNet Business Description

Address 8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222
RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians with individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments and the latest software for patient and physician satisfaction. It allows heliosDX to provide physicians with fast and accurate reporting meetings. The firm excels in patient and client care through physician-designed panels that aid in testing compliance and reporting education.